This is a non-core endpoint: only basic statistics are computed.
Chronic myeloid leukaemia
C3_CML
obsolete_chronic myeloid leukemia: ['Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.']
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
162 |
4. Check minimum number of eventsNone |
162 |
5. Include endpointsNone |
162 |
6. Filter based on genotype QC (FinnGen only) |
155 |
Control definitions (FinnGen only)
- Control exclude
- C3_CANCER, C3_CANCER_WIDE
Extra metadata
- Level in the ICD hierarchy
- C
- First used in FinnGen datafreeze
- DF8
Similar endpoints
↥List of similar endpoints to
Chronic myeloid leukaemia
based on the number of shared cases.
Similar with more cases:
- Chronic myeloid leukaemia, including Hilmo
- Primary_lymphoid and hematopoietic malignant neoplasms
- Liquid cancers, helper endpoint
- Malignant neoplasm
- Any event in cancer register
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 155 | 70 | 85 |
| Unadjusted period prevalence (%) | 0.03 | 0.02 | 0.04 |
| Median age at first event (years) | 60.02 | 57.59 | 62.02 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 162
- Matched controls
- 1620
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
C92.1
ICD-10 Finland
Chronic myeloid leukaemia [CML], BCR/ABL-positive
+∞
225.4
159
*
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
2603.0
196.6
154
11
9863/3-C42.1
ICD-O-3
Chronic myeloid leukemia, NOS, of bone marrow
+∞
179.1
137
*
XW000
NOMESCO Finland
Bone marrow biopsy
105.3
164.2
90
19
189
Kela drug reimbursment
Imatinib
+∞
145.7
117
*
L01XE01
ATC
[U] imatinib
+∞
111.8
94
*
M04AA01
ATC
allopurinol; systemic
22.1
92.8
109
138
316
Kela drug reimbursment
Imatinib
+∞
67.5
60
*
L01EA01
ATC
imatinib; oral
+∞
67.5
60
*
L01XX05
ATC
hydroxycarbamide; oral
104.5
57.0
60
9
C92.0
ICD-10 Finland
Acute myeloblastic leukaemia [AML]
+∞
39.2
36
*
152
Kela drug reimbursment
Nilotinib
+∞
38.0
35
*
D72.8
ICD-10 Finland
Other specified disorders of white blood cells
158.5
36.4
37
*
L01XX28
ATC
[U] imatinib
+∞
34.6
32
*
150
Kela drug reimbursment
Dasatinib
+∞
30.1
28
*
L03AA02
ATC
filgrastim; parenteral
+∞
27.9
26
*
L01XE08
ATC
[U] nilotinib
+∞
27.9
26
*
C91.1
ICD-10 Finland
Chronic lymphocytic leukaemia of B-cell type
+∞
24.6
23
*
L01XE06
ATC
[U] dasatinib
+∞
24.6
23
*
328
Kela drug reimbursment
Nilotinib
+∞
24.6
23
*
L01EA03
ATC
nilotinib; oral
+∞
22.4
21
*
9875/3-C42.1
ICD-O-3
Chronic myelogenous leukemia, BCR/ABL positive of bone marrow
+∞
22.4
21
*
127
Kela drug reimbursment
Transplant complication
93.4
22.3
24
*
212
Kela drug reimbursment
Gout
24.2
21.3
30
15
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
6.3
20.5
41
83
324
Kela drug reimbursment
Dasatinib
+∞
19.1
18
*
L01EA02
ATC
dasatinib; oral
+∞
18.0
17
*
L04AA01
ATC
[U] ciclosporin
176.3
15.8
16
*
J01EE01
ATC
sulfamethoxazole and trimethoprim; systemic
7.5
14.9
23
35
C61
ICD-10 Finland
Malignant neoplasm of prostate
+∞
13.7
13
*
170
Kela drug reimbursment
Bosutinib
+∞
13.7
13
*
A04AA01
ATC
ondansetron; systemic, rectal
17.0
13.5
21
14
8140/3-C61.9
ICD-O-3
Adenocarcinoma, NOS, of prostate gland
+∞
11.6
11
*
R50.9
ICD-10 Finland
Fever, unspecified
4.0
11.6
39
119
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
5.1
11.2
26
59
A49.9
ICD-10 Finland
Bacterial infection, unspecified
4.4
11.1
31
82
D75.9
ICD-10 Finland
Disease of blood and blood-forming organs, unspecified
46.8
11.1
13
*
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
5.5
10.6
22
45
C44.31
ICD-10 Finland
Basocellular carcinoma of the skin on another or unspecified part of the face
117.3
10.5
11
*
L03AA04, ,
ATC
+∞
10.5
10
*
360
Kela drug reimbursment
Bosutinib
+∞
10.5
10
*
WW500
NOMESCO Finland
Blood transfusion
12.5
10.4
18
16
A03FA01
ATC
metoclopramide; systemic, rectal
3.8
10.3
36
112
A01AB04
ATC
amphotericin B; local oral
5.7
9.6
19
37
T86.0
ICD-10 Finland
Bone-marrow transplant rejection
106.0
9.5
10
*
C92.9
ICD-10 Finland
Myeloid leukaemia, unspecified
+∞
9.5
9
*
C95.0
ICD-10 Finland
Acute leukaemia of unspecified cell type
+∞
9.5
9
*
L01EA04
ATC
bosutinib; oral
+∞
9.5
9
*
115
Kela drug reimbursment
Breast cancer
+∞
9.5
9
*
N02AA05
ATC
oxycodone; systemic
3.6
9.4
36
119
JN4BD
NOMESCO Finland
Extensive body CT
5.5
9.3
19
38
WW200
NOMESCO Finland
Immunization
12.5
9.3
16
14
Y84
ICD-10 Finland
Other medical procedures as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure
39.1
9.1
11
*
TNE25
NOMESCO Finland
Drill biopsy of bone marrow, pelvis
25.7
9.0
12
5
A05AA02
ATC
ursodeoxycholic acid; oral
15.2
8.9
14
10
WZC00
NOMESCO Finland
Treatment plan or consultation
2.9
8.7
56
252
PJA12
NOMESCO Finland
Sentinel node biopsy
+∞
8.4
8
*
L03AB05
ATC
interferon alfa-2b; parenteral
+∞
8.4
8
*
8090/3-C44.9
ICD-O-3
Basal cell carcinoma, NOS, of skin, NOS
+∞
8.4
8
*
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.6
8.2
90
526
D72.9
ICD-10 Finland
Disorder of white blood cells, unspecified
23.4
8.1
11
5
C03CA01
ATC
furosemide; systemic
2.6
8.1
67
341
121
Kela drug reimbursment
Severe hypofunction of sexual glands
14.0
8.0
13
10
J01MA14
ATC
moxifloxacin; systemic
4.0
7.9
24
67
NEA10
NOMESCO Finland
Exploration of soft tissue of pelvis, percutaneous
47.3
7.8
9
*
D46.7
ICD-10 Finland
Other myelodysplastic syndromes
47.3
7.8
9
*
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
83.8
7.5
8
*
B03XA01
ATC
erythropoietin; parenteral
83.8
7.5
8
*
WW302
NOMESCO Finland
Allogenic transfer of stem cells from relative
+∞
7.3
7
*
C50.41
ICD-10 Finland
Malignant tumor of the upper outer quadrant of the mammary gland, ductal tumor
+∞
7.3
7
*
2051A
ICD-9 Finland
Myeloid leukaemia, Chronic
+∞
7.3
7
*
Z51.5
ICD-10 Finland
Palliative care
8.6
7.3
15
19
B03XA02
ATC
darbepoetin alfa; parenteral
21.2
7.2
10
5
JN4AD
NOMESCO Finland
Body CT examination
4.6
7.2
18
43
B01AB10
ATC
tinzaparin; parenteral
4.3
6.9
19
49
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
2.4
6.6
62
329
N02AB03
ATC
fentanyl; nasal, sublingual, transdermal
15.1
6.5
10
7
D46.9
ICD-10 Finland
Myelodysplastic syndrome, unspecified
72.6
6.5
7
*
L02AE02
ATC
leuprorelin; implant, parenteral
72.6
6.5
7
*
B25.8
ICD-10 Finland
Other cytomegaloviral diseases
27.9
6.3
8
*
373
Kela drug reimbursment
Ponatinib
+∞
6.3
6
*
8500/3-C50.9
ICD-O-3
Infiltrating duct carcinoma, NOS, of breast, NOS
+∞
6.3
6
*
116
Kela drug reimbursment
Prostate cancer
+∞
6.3
6
*
8090/3-C44.3
ICD-O-3
Basal cell carcinoma, NOS, of skin of other and unspecified parts of face
+∞
6.3
6
*
C95.9
ICD-10 Finland
Leukaemia, unspecified
+∞
6.3
6
*
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
6.0
6.2
16
29
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
4.3
6.1
16
40
TPH04
NOMESCO Finland
Cathetrisation of vein
2.6
6.0
41
186
Z3231
NOMESCO Finland
Registered nurse
2.4
6.0
51
257
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
65
0
+∞
73.69
16.0
0.0
—
—
—
0
0
49
0
+∞
54.26
12.1
0.0
—
—
—
0
0
124
591
5.68
22.10
16.4
5.3
1.21
1.22
mmol/l
0.04
112
514
18
0
+∞
19.13
7.2
0.0
36.22
—
u/l
—
18
0
55
170
4.38
16.52
3.8
2.2
21.21
23.04
%
0.51
45
151
23
13
20.38
15.68
1.1
1.1
—
—
—
0
0
67
299
3.12
10.91
2.8
2.1
2.51
2.90
mg/l
0.99
62
252
17
14
13.40
10.12
1.1
1.0
—
—
—
0
0
20
24
9.34
9.90
1.5
1.1
—
—
—
0
0
16
13
13.50
9.59
1.9
1.5
—
—
—
0
0
16
13
13.50
9.59
1.9
1.5
—
—
—
0
0
9
0
+∞
9.46
1.0
0.0
—
—
—
0
0
20
27
8.29
9.26
1.5
1.7
—
—
—
0
0
14
9
16.87
9.21
1.4
1.7
—
—
—
0
0
14
9
16.87
9.21
1.4
1.7
—
—
—
0
0
16
15
11.69
9.02
3.6
1.6
—
637.40
—
0
5
16
18
9.73
8.26
1.9
1.4
—
—
—
0
0
79
437
2.58
8.02
4.9
3.0
—
—
—
0
0
15
17
9.60
7.73
2.0
1.4
—
—
—
0
0
44
185
2.89
7.63
2.8
1.7
—
—
—
0
0
36
136
3.12
7.53
2.7
1.8
—
—
—
0
0
7
0
+∞
7.34
1.0
0.0
—
—
—
0
0
10
5
21.17
7.22
1.2
2.0
2.55
3.20
mg/l
—
10
5
35
137
2.98
6.85
2.7
1.7
—
—
—
0
0
14
18
8.40
6.77
5.7
4.1
53.00
59.94
%
0.81
14
18
9
5
18.94
6.34
1.0
1.0
—
—
—
0
0
83
510
2.29
6.24
4.5
2.2
—
—
—
0
0
46
219
2.54
6.15
4.7
1.9
2.47
2.44
mmol/l
0.25
46
188
13
18
7.75
6.06
5.5
3.3
2.78
5.09
e9/l
2.28
13
18
8
5
16.71
5.47
9.9
2.0
—
—
—
0
0
10
11
9.60
5.37
1.0
1.2
—
—
—
0
0
5
0
+∞
5.23
1.0
0.0
—
—
—
0
0
88
585
2.10
5.11
11.1
13.1
1.15
1.30
inr
1.15
22
162
19
64
3.23
4.74
1.5
1.2
—
—
—
0
0
12
22
5.80
4.70
1.0
1.0
—
—
—
0
0
59
348
2.09
4.61
4.5
2.7
0.30
0.37
e6/l
0.22
51
248
47
258
2.16
4.40
3.8
1.9
—
—
—
0
0
10
16
6.58
4.36
1.5
1.3
—
—
—
0
0
9
13
7.26
4.22
2.0
1.2
—
—
—
0
0
30
139
2.42
4.15
10.3
5.7
-0.02
1.60
mmol/l
0.72
21
113
66
421
1.96
4.06
5.5
2.1
171.74
212.04
u/l
0.42
66
400
12
28
4.54
3.90
1.9
1.4
—
—
—
0
0
79
541
1.90
3.89
2.4
2.0
90.25
96.54
pmol/l
0.51
55
275
7
8
9.08
3.81
1.6
1.4
474.14
481.13
u/l
—
7
8
7
8
9.08
3.81
1.3
2.3
791.43
716.75
e6/l
—
7
8
11
25
4.64
3.70
2.5
3.1
175.55
191.24
%
0.24
11
25
6
6
10.32
3.52
1.3
2.7
—
—
—
0
0
6
6
10.32
3.52
1.3
2.7
—
—
—
0
0
13
37
3.73
3.49
1.7
4.1
—
—
—
0
0
37
202
2.08
3.45
5.0
2.7
2.93
3.11
e6/l
0.04
22
103
18
72
2.69
3.34
1.6
1.6
—
—
—
0
0
53
336
1.86
3.20
1.9
1.6
19.45
21.08
nmol/l
0.37
48
286
38
217
1.98
3.12
3.7
2.5
1.52
1.25
e6/l
0.16
24
117
6
8
7.73
3.08
1.0
1.3
—
—
—
0
0
18
78
2.47
2.86
1.9
1.4
—
—
—
0
0
9
23
4.08
2.82
1.9
1.5
—
—
—
0
0
5
6
8.55
2.77
1.0
1.0
—
—
—
0
0
7
14
5.17
2.76
1.6
1.0
—
—
—
0
0
6
10
6.18
2.72
2.5
1.2
—
—
—
0
0
8
20
4.15
2.60
1.3
1.3
—
—
—
0
0
8
20
4.15
2.60
1.3
1.3
—
—
—
0
0
5
7
7.32
2.56
3.2
1.1
—
—
—
0
0
5
7
7.32
2.56
3.2
1.1
—
—
—
0
0
5
7
7.32
2.56
3.2
1.1
—
—
—
0
0
5
7
7.32
2.56
1.6
1.6
—
—
—
0
0
43
272
1.79
2.56
2.0
1.7
1.40
1.05
mg/l
0.47
35
207
6
12
5.15
2.42
1.5
1.0
—
—
—
0
0
6
12
5.15
2.42
2.7
1.2
—
—
—
0
0
10
33
3.16
2.40
1.7
1.3
—
—
—
0
0
6
13
4.75
2.29
1.8
1.3
—
—
—
0
0
16
76
2.23
2.10
1.4
1.5
—
—
—
0
0
123
1083
1.56
1.63
51.4
14.6
14.65
14.99
%
0.79
123
1066
5
14
3.65
1.62
1.2
1.7
—
—
—
0
0
40
283
1.55
1.52
6.7
3.8
209.51
244.67
ng/l
0.08
35
224
89
746
1.43
1.42
2.7
2.8
—
—
—
0
0
8
38
2.16
1.20
2.0
1.4
—
—
—
0
0
73
613
1.35
1.07
4.3
3.7
0.00
0.00
estimate
-0.00
12
96
71
604
1.31
0.92
5.4
5.1
0.00
0.00
estimate
-0.00
13
99
70
600
1.29
0.84
4.3
3.6
0.00
0.00
estimate
-0.00
12
111
137
1288
1.41
0.82
37.6
12.1
18.83
22.60
mg/l
0.94
124
978
10
58
1.77
0.81
1.1
1.8
—
163.33
—
0
6
5
26
1.95
0.71
1.4
1.3
—
—
—
0
0
8
54
1.51
0.58
3.4
1.9
330.70
427.05
ug/l
—
8
47
12
82
1.50
0.56
5.6
2.5
1.23
1.22
mmol/l
0.32
12
67
6
40
1.52
0.52
1.8
1.4
—
—
—
0
0
6
40
1.52
0.52
4.2
1.6
—
—
—
0
0
139
1437
0.77
0.48
56.9
17.8
37.40
40.55
%
7.14
129
1346
5
34
1.49
0.40
1.0
1.4
—
—
—
0
0
0
19
0.00
0.39
0.0
1.6
—
—
—
0
0
0
19
0.00
0.39
0.0
1.2
—
—
—
0
0
0
19
0.00
0.39
0.0
1.0
—
—
—
0
0
36
312
1.20
0.37
5.7
3.7
0.00
0.00
estimate
-0.00
11
100
47
419
1.17
0.36
3.9
3.9
17.43
7.07
mg/mmol
0.46
32
270
7
95
0.73
0.23
1.3
1.6
—
—
—
0
0
5
40
1.26
0.22
1.4
1.2
—
—
—
0
0
5
41
1.23
0.22
1.0
1.4
—
—
—
0
0
0
11
0.00
0.21
0.0
1.7
—
—
—
0
0
0
11
0.00
0.21
0.0
1.7
—
—
—
0
0
0
11
0.00
0.21
0.0
1.7
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
57
534
1.10
0.20
4.0
3.5
21.81
47.11
ng/l
2.42
44
383
0
14
0.00
0.20
0.0
1.8
—
—
—
0
0
0
14
0.00
0.20
0.0
1.3
—
—
—
0
0
18
204
0.87
0.17
1.6
1.4
—
—
—
0
0
125
1223
1.10
0.15
35.1
10.9
73.38
79.96
ml/min/173m2
2.20
115
995
9
106
0.84
0.13
1.2
1.8
—
—
—
0
0
9
105
0.85
0.13
1.4
1.8
—
—
—
0
0
13
145
0.89
0.10
1.5
1.3
—
—
—
0
0
55
529
1.06
0.09
4.3
3.8
1.73
1.77
ug/l
0.06
50
471
5
60
0.83
0.08
1.4
1.3
—
—
—
0
0
7
63
1.12
0.08
3.6
2.2
1.39
1.23
%
—
7
63
29
275
1.07
0.07
1.4
1.9
487.74
463.82
pmol/l
0.09
23
223
28
295
0.94
0.07
2.5
2.6
0.70
0.73
ug/l
0.06
17
184
138
1369
1.05
0.04
44.8
14.2
93.16
79.10
umol/l
2.62
138
1369
15
159
0.94
0.03
10.5
6.3
—
—
—
0
0
12
112
1.08
0.03
4.7
2.9
—
—
—
0
0
47
479
0.97
0.02
5.2
3.7
—
—
—
0
0
13
129
1.01
0.00
2.2
2.4
4.42
9.26
ug/l
1.24
13
115
24
236
1.02
0.00
1.3
1.2
16.79
49.17
iu/ml
—
9
73
120
1204
0.99
0.00
6.3
6.3
38.53
40.28
mmol/mol
1.83
114
1123
42
416
1.01
0.00
3.6
3.6
25.25
24.05
%
0.16
19
171
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.7
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.5
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.5
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: C3_CML – Chronic myeloid leukaemia
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).